Urology | Home | MIMS Malaysia

Tumour volume-related parameters after radical prostatectomy do not enhance recurrence prediction

16 hours ago

A significant association exists between tumour volume-related parameters and radical prostatectomy, suggests a study. However, these parameters do not add important discriminatory value to standard clinicopathological variable for radical prostatectomy prediction or provide benefit across a range of clinically relevant decision thresholds.

Thermal therapy provides durable lower urinary tract symptom relief in BPH patients

3 days ago

The minimally invasive water vapour thermal therapy represents a viable approach for thermal ablative reduction of benign prostate hyperplasia (BPH), providing urinary symptom relief and quality of life improvement that are sustained over 4 years, a study has shown.

Paroxetine outdoes fluoxetine, escitalopram for premature ejaculation

Audrey Abella, 07 Feb 2019

The selective serotonin reuptake inhibitor paroxetine fared better than fluoxetine and escitalopram in managing premature ejaculation (PE), demonstrating improved intravaginal ejaculatory latency time (IELT), according to a meta-analysis. Moreover, combining paroxetine with tadalafil or behavioural therapy was better than paroxetine alone in improving IELT.

Unravelling the puzzle: Tips for managing erectile dysfunction in hypertensive patients

Dr. Joe Lee, 12 Apr 2018

A 70-year-old male with a history of diabetes, hyperlipidaemia and hypertension managed with atenolol presented to his family physician with lower urinary tract symptoms (LUTS). He was prescribed terazosin. Over the course of a year he noticed worsening erectile dysfunction (ED) with difficulty maintaining a hard erection until orgasm.

Nocturia: An inside view on key causes and principles of management

02 Nov 2017

Nocturia is the most prevalent of the lower urinary tract symptoms (LUTS) and can cause a significant negative impact on an individual’s quality of life if left untreated.1,2 In a meeting held at University Malaya Medical Centre, Associate Professor Dr Ong Teng Aik shared his insights on the management of nocturia.

Refining the role of combination therapy for the medical management of benign prostatic hyperplasia

15 Jun 2017

At a recent morning tea symposium held in conjunction with the Malaysian Urological Conference 2016, Dr Marie Carmela Lapitan discussed about the benefits of combination therapy with alpha-blockers and 5-alpha-reductase inhibitors (5-ARIs) for the management of benign prostatic hyperplasia (BPH).

Androgen deprivation therapy associated with depression in elderly prostate cancer patients

Roshini Claire Anthony, 25 Apr 2016

Elderly patients on androgen deprivation therapy (ADT) as part of prostate cancer treatment may be at an increased risk of depression, a recent study states.

Prostate cancer biomarker research gains momentum, but challenges remain

Jackey Suen, 30 Jan 2019

Recent research has revealed various potential biomarkers for metastatic castration-resistant prostate cancer (mCRPC), but several challenges remain in fully utilizing them in clinical practice.

Nanotechnology structured water shows potential for ED treatment

Audrey Abella, 11 May 2018

Nanotechnology structured water was similarly effective as tadalafil in improving erectile function, suggesting that it could be a potential treatment option for erectile dysfunction (ED), according to a study presented at EAU held in Copenhagen, Denmark.

Vibegron shows potential as OAB treatment

Audrey Abella, 30 Apr 2018

The selective β3-adrenoreceptor (AR) agonist vibegron showed superior efficacy over placebo for overactive bladder (OAB) treatment and was generally well-tolerated, according to a Japanese study presented at EAU 2018.

No benefit to targeted antibiotic prophylaxis before TRUS-guided prostate biopsy

Roshini Claire Anthony, 23 Apr 2018

Targeted antibiotic prophylaxis – after a rectal swab to identify specific intestinal flora – does not appear to significantly impact the risk of urinary sepsis following a transrectal ultrasound (TRUS)-guided prostate biopsy, according to a recent study.

Conservative management trumps early urinary tract drainage in non-penetrating renal trauma

Roshini Claire Anthony, 20 Apr 2018

Conservative management appears to be the favoured option in managing non-penetrating renal trauma with urinary extravasation, according to a study presented at EAU 2018.

MRI before biopsy better than TRUS in prostate cancer diagnosis

Christina Lau, 16 Apr 2018

MRI, with or without targeted biopsy, detects more clinically significant prostate cancer and less clinically insignificant prostate cancer than the standard transrectal ultrasonography (TRUS)-guided approach, enabling more than one-quarter of patients to safely avoid a biopsy altogether.

Apalutamide offers similar HRQoL vs ADT alone in nonmetastatic castration-resistant prostate cancer

Christina Lau, 12 Apr 2018

Men with nonmetastatic castration-resistant prostate cancer (CRPC) have similar health-related quality of life (HRQoL) with apalutamide given on top of androgen deprivation therapy (ADT) vs ADT alone, according to new data from the SPARTAN (Prostate Androgen Receptor Targeting with ARN-509) trial presented at the European Association of Urology (EAU) 2018 Congress.